Successful treatment of disseminated granuloma annulare with topical tacrolimus

Jain, Sanjay; Stephens, C.J.M.

doi:10.1111/j.1365-2133.2004.05947.x

Cited by 40 publications

(25 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…29 Patients must be counseled on risks of corticosteroid use (both topical and intralesional), in particular the risk of atrophy, dyschromia, and striae. 29 Topical tacrolimus has also been reported in the successful treatment of perforating, periorbital, and disseminated GA. [87][88][89][90][91] These results may be related to the recent report of glioma-associated oncogene (gli-1) highly expressed in granulomatous skin disorders, including GA, 92 and may offer future therapeutic options for patients with disseminated and recalcitrant disease.…”

Section: Evaluation and Managementsupporting

confidence: 49%

“…Immunosuppression with methotrexate, cyclosporine, and TNF-a inhibitors can be considered in patients with severe disease that has been recalcitrant to other therapies. 28,[87][88][89][90][91][93][94][95][96][97][98][99][100][101][102][103][104][105][106][107][108][109][114][115][116][117][118][119][120][121][122][123][124]126,127,129,130,[132][133][134][140][141][142][144][145][146][147][148]150,…”

Section: Evaluation and Managementmentioning

confidence: 99%

See 1 more Smart Citation

Granuloma Annulare

Keimig

2015

Dermatologic Clinics

View full text Add to dashboard Cite

Granuloma annulare (GA) is a noninfectious granulomatous skin condition that can present with a variety of cutaneous morphologies. It is characterized by collagen degeneration, mucin deposition, and palisaded or interstitial histiocytes. Although the mechanism underlying development of GA is unknown, studies point to a cell-mediated hypersensitivity reaction to an as-yet undetermined antigen. Systemic associations with diabetes, thyroid disorders, lipid abnormalities, malignancy, and infection are described in atypical GA. Treatment is divided into localized skin-directed therapies and systemic immunomodulatory or immunosuppressive therapies. The selected treatment modality should be based on disease severity, comorbid conditions, consideration of potential side effects, and patient preference.

show abstract

Section: Evaluation and Managementsupporting

confidence: 49%

Section: Evaluation and Managementmentioning

confidence: 99%

Granuloma Annulare

Keimig

2015

Dermatologic Clinics

View full text Add to dashboard Cite

show abstract

“…This hypothesis is supported by a recent report showing that patients with disseminated GA could be treated successfully with topical tacrolimus, another topical immunomodulator. 12 It is difficult to interpret whether clinical improvement of the patient was caused by our novel combination therapy or by spontaneous regression. However, the disease progression of our patient had been stopped shortly after the beginning of treatment and complete remission had been achieved.…”

Section: Discussionmentioning

confidence: 98%

Annular elastolytic giant cell granuloma in an infant: Improvement after treatment with oral tranilast and topical pimecrolimus

Lee

Choi

et al. 2005

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…These cases clearly represent a major therapeutic challenge and many patients remain troubled by the appearance. The visible and unsightly nature of this skin condition has led to the proposal of a variety of topical and/or systemic treatment methods [5][6][7][8][9][10][11][12][13][14][15] (Table 1)-all with varying degrees of success and each with its own treatment-associated morbidity.…”

Section: Introductionmentioning

confidence: 99%